A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

被引：0

作者：

Taiga Otsuka

Tsuyoshi Shirakawa

Mototsugu Shimokawa

Futa Koga

Yasunori Kawaguchi

Yujiro Ueda

Junichi Nakazawa

Azusa Komori

Satoshi Otsu

Shiho Arima

Masaru Fukahori

Yoshinobu Okabe

Akitaka Makiyama

Hiroki Taguchi

Takuya Honda

Taro Shibuki

Kenta Nio

Yasushi Ide

Toshihiko Mizuta

Kenji Mitsugi

Norio Ureshino

机构：

[1] Saga Medical Center Koseikan,Department of Medical Oncology

[2] Minato Medical Clinic,Department of Internal Medicine

[3] Fukuoka Wajiro Hospital,Department of Medical Oncology

[4] Karatsu Higashi-Matsuura Medical Association Center,Clinical Research Institute

[5] National Kyushu Cancer Center,Department of Biostatistics

[6] Yamaguchi University Graduate School of Medicine,Department of Hepatobiliary and Pancreatology

[7] Saga Medical Center Koseikan,Department of Gastroenterology

[8] Asakura Medical Association Hospital,Department of Hematology and Oncology

[9] Japanese Red Cross Kumamoto Hospital,Department of Medical Oncology

[10] Kagoshima City Hospital,Department of Medical Oncology and Hematology

[11] Oita University Faculty of Medicine,Digestive and Lifestyle Diseases

[12] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Internal Medicine, Division of Gastroenterology

[13] Kurume University Hospital,Department of Hematology/Oncology

[14] Japan Community Healthcare Organization Kyushu Hospital,Department of Gastroenterology

[15] Cancer Center,Department of Gastroenterology

[16] Gifu University Hospital,Department of Gastroenterology and Hepatology

[17] Saiseikai Sendai Hospital,Department of Internal Medicine

[18] Izumi General Medical Center,Department of Hepatobiliary and Pancreatic Oncology

[19] Nagasaki University Graduate School of Biomedical Sciences,Department of Medical Oncology

[20] Imari Arita Kyoritsu Hospital,Department of Internal Medicine

[21] Saga,Department of Internal Medicine

[22] National Cancer Center Hospital East,Department of Medical Oncology

[23] Sasebo Kyosai Hospital,Department of Medical Oncology

[24] Karatsu Red Cross Hospital,undefined

[25] Fujikawa Hospital,undefined

[26] Hamanomachi Hospital,undefined

[27] Kimitsu Chuo Hospital,undefined

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Pancreatic cancer; FOLFIRINOX; Gemcitabine; Nab-paclitaxel; Propensity score analysis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：941 / 950

页数：9

共 50 条

[41] Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine [J].

Di Costanzo, Francesco ;

Di Costanzo, Federica ;

Antonuzzo, Lorenzo ;

Mazza, Ernesto ;

Giommoni, Elisa .

CANCERS, 2023, 15 (02)

[42] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer [J].

Chiorean, E. Gabriela ;

Von Hoff, Daniel D. ;

Tabernero, Josep ;

El-Maraghi, Robert ;

Ma, Wen Wee ;

Reni, Michele ;

Harris, Marion ;

Whorf, Robert ;

Liu, Helen ;

Li, Jack Shiansong ;

Manax, Victoria ;

Romano, Alfredo ;

Lu, Brian ;

Goldstein, David .

BRITISH JOURNAL OF CANCER, 2016, 115 (02) :188-194

[43] Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response [J].

Nguyen, Khanh T. ;

Kalyan, Aparna ;

Beasley, H. Scott ;

Singhi, Aatur D. ;

Sun, Weijing ;

Zeh, Herbert J. ;

Normolle, Daniel ;

Bahary, Nathan .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) :556-565

[44] Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis [J].

Hayuka, Kotone ;

Okuyama, Hiroyuki ;

Murakami, Akitsu ;

Okita, Yoshihiro ;

Nishiuchi, Takamasa ;

Okano, Keiichi ;

Suzuki, Yasuyuki ;

Tsuji, Akihito .

CHEMOTHERAPY, 2021, 66 (03) :58-64

[45] Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment [J].

Giordano, Guido ;

Milella, Michele ;

Landriscina, Matteo ;

Bergamo, Francesca ;

Tirino, Giuseppe ;

Santaniello, Antonio ;

Zaniboni, Alberto ;

Vasile, Enrico ;

De Vita, Ferdinando ;

Lo Re, Giovanni ;

Vaccaro, Vanja ;

Giommoni, Elisa ;

Natale, Donato ;

Conca, Raffaele ;

Santini, Daniele ;

Maiorino, Luigi ;

Sanna, Gianni ;

Ricci, Vincenzo ;

Iop, Aldo ;

Montesarchio, Vincenzo ;

Procaccio, Letizia ;

Noventa, Silvia ;

Bianco, Roberto ;

Febbraro, Antonio ;

Lonardi, Sara ;

Tortora, Giampaolo ;

Sperduti, Isabella ;

Melisi, Davide .

CANCER MEDICINE, 2024, 13 (12)

[46] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma [J].

Grierson, Patrick M. ;

Tan, Benjamin ;

Pedersen, Katrina S. ;

Park, Haeseong ;

Suresh, Rama ;

Amin, Manik A. ;

Trikalinos, Nikolaos A. ;

Knoerzer, Deborah ;

Kreider, Brent ;

Reddy, Anupama ;

Liu, Jingxia ;

Der, Channing J. ;

Wang-Gillam, Andrea ;

Lim, Kian-Huat .

ONCOLOGIST, 2023, 28 (02) :E115-E123

[47] Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial [J].

Kamata, Ken ;

Imai, Hajime ;

Matsumoto, Hisakazu ;

Yamashita, Yukitaka ;

Kato, Takao ;

Nishi, Katsuhisa ;

Omoto, Shunsuke ;

Minaga, Kosuke ;

Yamao, Kentaro ;

Hyodo, Tomoko ;

Im, Sung-Woon ;

Hara, Akane ;

Yoshikawa, Tomoe ;

Ishikawa, Rei ;

Okamoto, Ayana ;

Yamazaki, Tomohiro ;

Nakai, Atsushi ;

Ueshima, Kazuomi ;

Chiba, Yasutaka ;

Takenaka, Mamoru ;

Watanabe, Tomohiro ;

Kitano, Masayuki ;

Kudo, Masatoshi .

JGH OPEN, 2023, 7 (09) :659-666

[48] Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis [J].

Pusceddu, Sara ;

Ghidini, Michele ;

Torchio, Martina ;

Corti, Francesca ;

Tomasello, Gianluca ;

Niger, Monica ;

Prinzi, Natalie ;

Nichetti, Federico ;

Coinu, Andrea ;

Di Bartolomeo, Maria ;

Cabiddu, Mary ;

Passalacqua, Rodolfo ;

de Braud, Filippo ;

Petrelli, Fausto .

CANCERS, 2019, 11 (04)

[49] Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer Using Korean Pancreatic Cancer (K-PaC) Registry [J].

Lee, Jong-chan ;

Woo, Sang Myung ;

Shin, Dong Woo ;

Kim, Jinkook ;

Yang, Se Yeol ;

Kim, Min Jae ;

Kim, Jin Won ;

Kim, Ji-Won ;

Lee, Woo Jin ;

Cha, Hyo Soung ;

Park, Philiip ;

Kim, Jaihwan ;

Hwang, Jin-Hyeok .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (09) :654-659

[50] Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX [J].

Peixoto, Renata D. ;

Ho, Maria ;

Renouf, Daniel J. ;

Lim, Howard J. ;

Gill, Sharlene ;

Ruan, Jenny Y. ;

Cheung, Winson Y. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (05) :507-511

← 1 2 3 4 5 →